Dangers of rosuvastatin identified before and after FDA approval
- 26 June 2004
- journal article
- other
- Published by Elsevier in The Lancet
- Vol. 363 (9427) , 2189-2190
- https://doi.org/10.1016/s0140-6736(04)16513-6
Abstract
No abstract availableKeywords
This publication has 1 reference indexed in Scilit:
- Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapyPharmacoepidemiology and Drug Safety, 2004